PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. The collaboration brings together ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience to develop high-quality iPSC-derived motor neuron models that can be used to test therapies, inform clinical trial design, and identify distinct biological subtypes of ALS/MND.

PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. The collaboration brings together ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience to develop high-quality iPSC-derived motor neuron models that can be used to test therapies, inform clinical trial design, and identify distinct biological subtypes of ALS/MND.

A letter from Zach Zangl, who was diagnosed with ALS in 2024 and now serves as a board member of ALS 100—a golf event that brings together elite players to complete 100 holes in a single day to raise awareness and fund ALS research.